




RealRate

PHARMACEUTICAL 2022

Innovation1 Biotech Inc
Rank 451 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Innovation1 Biotech Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Innovation1 Biotech Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 12% points. The greatest weakness of Innovation1 Biotech Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 166% points.

The company's Economic Capital Ratio, given in the ranking table, is 86%, being 189% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	168
Cost of Goods Sold	1.4
Intangible Assets	0
Liabilities, Current	407
Liabilities, Non-Current	0
Other Assets	13
Other Compr. Net Income	0
Other Expenses	191
Other Liabilities	0
Other Net Income	0
Other Revenues	3.1
Property and Equipment	0.60
Research and Development	0
Selling, General and Administrative Expense	49

Output Variable	Value in 1000 USD
Assets	182
Liabilities	407
Expenses	242
Revenues	3.1
Stockholders Equity	-225
Net Income	-239
Comprehensive Net Income	-239
BaseVar	417
ECR before LimitedLiability	-248%
Economic Capital Ratio	86%